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Abstract
Background: Malignant transformation and progression of cancer are driven by the co-
evolution of cancer cells and their dysregulated tumor microenvironment (TME). Recent
studies on immunotherapy demonstrate the efficacy in reverting the anti-tumoral
function of T cells, highlighting the therapeutic potential in targeting certain cell types in
TME. However, the functions of other immune cell types remain largely unexplored.
Results: We conduct a single-cell RNA-seq analysis of cells isolated from tumor tissue
samples of non-small cell lung cancer (NSCLC) patients, and identify subtypes of tumor-
infiltrated B cells and their diverse functions in the progression of NSCLC. Flow cytometry
and immunohistochemistry experiments on two independent cohorts confirm the co-
existence of the two major subtypes of B cells, namely the naïve-like and plasma-like B
cells. The naïve-like B cells are decreased in advanced NSCLC, and their lower level is
associated with poor prognosis. Co-culture of isolated naïve-like B cells from NSCLC
patients with two lung cancer cell lines demonstrate that the naïve-like B cells suppress
the growth of lung cancer cells by secreting four factors negatively regulating the cell
growth. We also demonstrate that the plasma-like B cells inhibit cancer cell growth in the
early stage of NSCLC, but promote cell growth in the advanced stage of NSCLC. The
roles of the plasma-like B cell produced immunoglobulins, and their interacting proteins
in the progression of NSCLC are further validated by proteomics data.
Conclusion: Our analysis reveals versatile functions of tumor-infiltrating B cells and their
potential clinical implications in NSCLC.
Introduction
Non-small cell lung cancer (NSCLC) is the leading life-threatening cancer in the world
[1, 2]. With the advancement in surgery, radiotherapy, chemotherapy, and immuno-
therapy, the prognosis of NSCLC has been significantly improved [3], but the clinical
outcome of advanced-stage NSCLC remains unsatisfied. Recent studies reported the
responsiveness of immunotherapy is highly determined by the characteristics of tumor
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microenvironment (TME), the variations in which were manifested by different abun-
dance and functions of tumor-infiltrating lymphocytes (TIL), myeloid, and other stro-
mal cells. A systematic characterization of the landscape of the TME and the crosstalk
between different cell types lays the biological foundations for optimizing personalized
immunotherapies of NSCLC.
T cells and B cells are the most abundant lymphocyte populations and play pivotal roles
in the TME of solid tumors. While T cells have been widely studied and therapeutically
targeted in immunotherapy, unfortunately, currently approved immune checkpoint inhib-
itors only achieved 20–25% response rate in unscreened NSCLC [4–8]. Tumor-infiltrating
B cells are a key component of adaptive immunity with diverse functions. Inconsistent
anti-tumor effects of B cells in NSCLC have been reported [9]. The subtypes and mecha-
nisms of B cells in the TME of NSCLC and how they interact with cancer cells and other
stromal cell types remain largely unknown. Hence, a comprehensive characterization of
the NSCLC immuno-landscape including the distribution and role of immune cell sub-
types, especially B lymphocytes, is necessary for understanding the non-responsiveness
mechanisms and discovering novel biomarkers and therapeutic strategies.
B cell regulates immune responses and inflammation through antibody production
and inducing T cell activation and proliferation via antigen presentation [10, 11]. Re-
cent studies revealed that depletion of B cells using anti-IgM antibodies reduced tumor
burden in mouse, indicating a possible role of B cells in regulating cancer cells’ progres-
sion [12]. Indeed, several studies identified that the B cells activated the FcRγ receptors
on myeloid cells and further induced carcinogenesis of squamous cells [13]. Another
study revealed that B cells may promote metastasis of breast cancer via secretion of
HSPA4-targeting immunoglobins (IgG) via activating the CXCR4/SDF1α axis in tumor
cells [14]. Contrarily, several studies unveiled potential anti-tumor functions of B cells.
Depletion of B cells using antibodies against CD20 enhanced the progression of melan-
oma in mouse [15]. Activation of B cells can also increase the T cell-mediated anti-
tumor effects and has been directly utilized in complement-mediated tumor cell lysis
through the production of IgM, IgG, and IgG2b [16]. Noting the different B cell sub-
types and their interactions with other cell types may cause such varied double-edge ef-
fects, it is necessary to characterize B cells and other immune cell types in the TME at
single-cell resolution.
Single-cell transcriptome and data analysis enables a comprehensive characterization
of the cell types in TME with high resolution [17, 18]. Until 2020, single cell-based
characterization of immune landscape, transcriptome signature, and varied functions of
immune cells has been conducted for breast cancer [17], lung cancer [19], liver cancer
[20], colorectal cancer [21], melanoma [22], and head and neck cancer [23]. However,
those studies majorly focused on T cells [17–20] or stromal cells [24, 25], but the dis-
tinct subtypes of B cells, as well as their functions, were largely ignored.
In this study, we conducted a single-cell RNA-seq analysis of 115,545 cells in 11
NSCLC patients, to systematically examine the relation between tumor-infiltrating B
cell profiles and the clinical outcome of NSCLC patients. Our analysis identified the
co-existence of two classes of B cells in the TME of NSCLC. We further validated the
existence and determined the clinical impact of these two B cell subtypes by using im-
munohistochemistry and flow cytometry in two cohorts. Also, we performed functional
analyses to identify the mechanisms of the two classes of B cells in the progression of
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NSCLC. Collectively, our study not only included a high-quality single-cell transcrip-
tomic reference map of the TME of stage I–III NSCLC, but also provided mechanistic
explanations to the role of B cells in NSCLC and implicated promising therapeutic
potentials.
Results
Infiltration of immune cells in NSCLC
To systematically investigate the TME of the NSCLC, we performed single-cell RNA-
seq analysis using the fresh tumor samples collected immediately after surgery. Tumor
tissues from 11 patients with NSCLC, including 6 of stage I and 5 of stage III, were
digested with the collagenase IV and analyzed by scRNA-seq with a total of 115,545
single cells (Fig. 1a), while the red blood cells, the platelets, and the dead cells were re-
moved by gradient centrifuge with the Ficoll [26]. Detailed data processing procedures
are available in the “Methods” part. We merged the single-cell transcriptomic profiles
collected from different samples for a UMAP-based cell clustering analysis, the cell
types of which were further annotated by using known cell type-specific gene markers
[27]. In total, 22 distinct cell clusters were identified and annotated, including subtypes
of T cells, B cells, monocytes, tumor, and epidermal cells (Fig. 1b).
We identified six classes of T cells (C0, C1, C3, C11, C13, C21) (Fig. 1b, Add-
itional file 1: Figure S1, Additional file2: Table S1). The C0 and C11 cluster of T cells
are with high expression level of CD3E, CD8A, and CD8B, suggesting CD8+ T cells; the
C13 cluster of T cells expressed high level of NCAM1 (CD56), CD3E, and NKG7 and
low level of CD8A and CD8B, suggesting possible natural killer T (NKT) cells; the C1
cluster expressed CD3E and CD69 genes, indicating CD69+ T cells; the C21 expressed
high levels of CD4 and GZMB, indicating CD4+ CTLs; the C3 cluster is with high ex-
pression of FOXP3 and IL2RA (CD25), which are possible Tregs. We identified two
classes of B cell (C4, C6), which expressed CD79A (in C4 and C6) and MS4A1 (CD20)
(in C4). We identified five classes of tumor cells (C8, C9, C10, C18, C20), which
expressed the tumor cell marker genes EPCAM, CEACAM6, or MKI67. We also identi-
fied five classes of monocytes (C2, C5, C7, C12, C14), expressing CD14 and CD86. The
C2, C5, C7, and C14 expressed high levels of CD163 and MRC1 (CD206), suggesting
the majority of monocytes/macrophages in the TME are M2-polarization macrophage.
We also observed red blood cell (C19) expressing HBA1 and HBB, epidermal or vascu-
lar cells (C15 and C17) expressing COL3A1 and COL1A2 (in C15) or IGFBP7 (in C17),
and mast cells (C16) expressing TPSAB1 and TPSB2 in the scRNA-seq (Fig. 1c, Add-
itional file 1: Figure S1, Additional file 2: Table S1). We next detected the ratio of 22
types of cells in different patients. In accordance with previous observations [17], the
composition of each cell types was largely different across the 11 tumor samples
(Fig. 1d).
To identify the clinical impact of these cell types in NSCLC, we selected the top 20
genes that mostly determined the identity of each cell type by ROC analysis. Co-
relation between the expression level of these genes and the prognosis of the NSCLC
was further computed by multivariate Cox regressions in TCGA data (Additional file 3:
Table S2). We found that the genes exclusively expressed in C10 (tumor cell) (ave.cor =
0.178) are associated with poor prognosis (Fig. 1e), where ave.cor represents the
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averaged Pearson correlation coefficient. On the other hand, the C1 (CD69+ T cell)
(ave.cor = − 0.164) and C4 (B cell) (ave.cor = − 0.174) expressing genes are correlated
with favorable prognosis of NSCLC, implying possible tumor-suppressive functions of
these cells. It is noteworthy that the higher expression of the genes exclusively
expressed in the C4 B cell types, such as MS4A1 (also known as CD20 antigen), were
Fig. 1 Single-cell transcriptomic analysis reveals the transcriptome of cells in the microenvironment of lung
cancer. a Schematic illustration of the experimental design of this study. b Visualization of single-cell RNA-
seq data of 115,545 cells freshly isolated primary lung cancer by UMAP. c Representative gene expression in
22 subclasses of cells. d Distribution of the 22 subclasses among 11 patients with NSCLC. e, f The prognosis
value of the genes uniquely expressed in each class of the 22 cell types
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positively with favorable prognosis of NSCLC (Fig. 1e, f), suggesting a tumor-
suppressive function of C4 cells in the microenvironment of NSCLC. Noting the sig-
nificant association with prognosis, we further focused on the subtypes of B cells and
their biological characteristics in the TME of NSCLC.
Co-existence of multiple subclasses of B cells in NSCLC
To illustrate the characteristics of B cells in NSCLC, the cells in C4 and C6 clustered in
our NSCLC scRNA-seq were kept for further analysis. We also extracted normal
single-cell datasets from peripheral blood mononuclear cells (PBMCs) generated by
10X genomics. We then combined single-cell RNA-seq data of B cells in NSCLC and
in the blood (Fig. 2a). The B cells could be divided into two major groups (BC1 and
BC2); the PBMCs contain 91.8% BC1 cells and 8.2% BC2 cells, while the NSCLC sam-
ples contain 61.8% BC1 cells and 39.2% BC2 cells (Fig. 2b). The BC1 cells express
markers of naïve B cells, such as MS4A1 (CD20), CD19, CD22, TCL1A, and CD83, and
the BC2 cells express markers of the plasma B cells, such as CD38, TNFRSF17
(BCMA), and IGHG1/IGHG4 (Fig. 2c, d). To further investigate the distribution of the
two B cell subtypes across different stages of NSCLC, we analyzed the percentage of
the two cell types in stage I and stage III NSCLC. We found that the naïve-like B cells
were significantly lower in stage III compared to stage I (P < 0.001 by t test) (Fig. 2e).
We further examined the differentially expressed genes between the BC1 (naïve-like
B) cells in PBMC and the TME of NSCLC. A total of 73 differentially expressed genes
were identified by using ROC analysis (Fig. 2f). The BC1 cells in NSCLC overly
expressed RACK1, JUND, CD83, ELOB, NFKB1A, APOE, and GADD45B, while the
BC1 cells in PBMC overly expressed GNB2L1, GLTSCR2, NBEAL1, ALDOA, and
TCEB2 (Fig. 2f). We next performed cell-cell interaction analysis using the CellPho-
neDB algorithm [28] and identified a cell-cell interaction network among the two cell
types (and other cell types). It is noteworthy that the genes expressed by the B cells
showed a strong interaction with other immune cell types (Additional file 1: Figure S2),
suggesting an essential role of B cells in the microenvironment of NSCLC.
Naïve-like B cells are associated with good prognosis of NSCLC
To validate the co-existence of different B cells in the microenvironment of NSCLC
and determine the clinical relevance of each subtype of B cells, we performed co-
staining of CD79A and CD20 in the primary NSCLC tissues by immunohistochemistry
and immunofluorescence. As shown in Fig. 3a, a subset of cells express both CD79A
and CD20, while the rest express the CD79A only. We noticed that the CD20-positive
cells were mainly located at the tertiary lymphoid structures (TLS) of lung tumor tis-
sues while CD79A-positive cells were not only located at the TLS but also randomly
enriched within tumor tissues (Fig. 3b), suggesting CD20+ naïve-like B cells and
plasma-like B cells might function versatile in the lung cancers. We further applied a
flow cytometry analysis in a cohort of 30 NSCLC tumor tissues, including 10 stage I, 10
stage II, and 10 stage III fresh tissues. The flow cytometry also demonstrated the co-
existence of the two subtypes of B cells (Fig. 3c). In addition, we observed a decrease of
the CD20+CD79+ B cell in the advanced stages of NSCLC (Fig. 3d).
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To confirm this observation, we analyzed the clinical impact of infiltrating naïve-like
B cells in a cohort containing 164 NSCLC samples. We stained the 164 NSCLC sam-
ples with the antibodies against CD20 and CD79A and evaluated the infiltration level
of naïve-like B cells by using the ratio of CD20+CD79A+-positive cells in TILs. We
found that the infiltration level of naïve-like B cells was significantly decreased in stage
II (P = 0.01 by t test) and stage III NSCLC (P < 0.001 by t test) compared to stage I
NSCLC (Fig. 3e). We further divided the NSCLC samples into two groups, the naïve-
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Fig. 2 Co-existence of the two major subtypes of B cells in the microenvironment of NSCLC tumors. a
Schematic illustration of the analysis procedure. b Visualization of single-cell RNA-seq data of B cells by UMAP. c
Representative gene expression among different classes of B cells. d Expression of MS4A1 (CD20), CD22, CD19,
TNFRSF17 (BCMA), IGHG1, and IGHG4 in B cells. e Distribution of different subclasses of B cells in stage I and
stage III NSCLC. f Heatmap showing the difference of BC1 (naïve-like B cells) between NSCLC and PBMC
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Fig. 3 (See legend on next page.)
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CD20+CD79A+ cells in tumor tissues. We then compared the prognosis of the two
groups. We found that the higher infiltration levels of naïve-like B correlated with a
better overall survival (P < 0.01 by log-rank test) and relapse-free survival (P = 0.02 by
log-rank test) (Fig. 3f, Table 1).
We further examined the expression level of subtype-specific marker genes of the
two B cell types in different stages of lung cancer using the transcriptome datasets from
(See figure on previous page.)
Fig. 3 CD20+ B cells are associated with good prognosis of NSCLC. a, b Validation of the presence of
CD79A+CD20+ and CD79A+CD20− B cells in NSCLC tumors. Antibodies against CD79A and CD20 were used
for immunofluorescence and immunohistochemistry. a Co-staining of CD79A (red) and CD20 (green), as
well as the staining of CD79A only, was illustrated by immunofluorescence. b Immunohistochemistry
showing the distribution of CD79A and CD20 in NSCLC tissue. The CD20+ B cells were located at the
tertiary lymphoid structures (TLS) only, but the CD79+ B cells were located at both TLS and the tumor
regions. c, d Flow cytometry showing the CD79A+CD20+ cells were reduced in advanced stages of NSCLC.
c Representative illustration of flow cytometry results was plotted. d The ratio of CD79A+CD20+ and
CD79A+CD20− in 30 tumor tissues from I–III stages of NSCLC were plotted. e, f Patient with high levels of
infiltration of naïve-like B cells was associated with better clinical outcome of NSCLC. e The naïve-like B
score determined by immunohistochemistry in I–III stages of NSCLC was plotted. f The enrichment of
naïve-like B cells (Naïve-like Bhigh) was correlated with good prognosis of NSCLC in 164 patients. The
difference in overall survival and relapse-free-survival between Naïve-like Bhigh patients and Naïve-like Blow
patients was determined by log-rank test. The NSCLC tumors were divided into two subgroups, including
Naïve-like Bhigh and Naïve-like Blow according to the immunostaining of CD79A and CD20 across 164 NSCLC
tissues. g Validation using TCGA datasets. The mRNA level of MS4A1(CD20) in different stages of NSCLC as
well as normal control was plotted. MS4A1(CD20) was highly expressed in lung cancer as compared to
adjacent normal tissues but decreased in advanced stages of lung cancers in the TCGA cohort. h, i
Correlation between MS4A1(CD20) expression and PDCD1 (PD-1)/CD274 (PD-L1) as well as tumor mutation
burden of LUAD. The expression of MS4A1 (CD20) and PDCD1/CD274 was obtained from the TCGA-LUAD
cohorts. The tumor mutation burden (TMB) was calculated and divided into the high TMB and low
TMB groups
Table 1 Clinical relevance of naïve-like B cells in NSCLC
Clinical characteristics Naïve-like Blow(N = 105) Naïve-like Bhigh(N = 59) P value
Age 0.129
≤ 58 44 (50.5) 32 (67.8)
>58 61 (49.5) 27 (32.2)
Sex 0.517
Male 50 (47.6) 25 (42.4)
Female 55 (52.4) 34 (57.6)
Location 0.216
Left 31 (29.5) 23 (39)
Right 74 (70.5) 36 (61)
Tumor size 0.744
≤ 3 cm 74 (70.5) 43 (72.9)
>3 cm 31 (29.5) 16 (27.1)
N stage < 0.001
0 52 (49.5) 46 (78.0)
1–2 53 (50.5) 13 (12.0)
AJCC stage 0.006
I 30 (28.6) 31 (52.5)
II 34 (32.4) 16 (27.1)
II 41 (39.0) 12 (20.3)
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the LUAD TCGA cohorts. We identified that the expression of MS4A1 (CD20)
(Fig. 3g) were higher in tumor tissues compared to adjacent normal tissues and the
expression level of MS4A1 was significantly decreased in the advanced stages of
lung cancers (Fig. 3g). As the outcome of PD-1/PD-L1 inhibitors was mostly
dependent on the expression level of PD-1/PD-L1 and the tumor mutation burden
(TMB), we examined the association of B cell infiltration with the PD-1/PD-L1 ex-
pression and TMB in the TCGA cohort. The higher level of B cell infiltration was
positively correlated with higher expression of both PD-1/PD-L1 and the TMB
level (Fig. 3h, i), implying the high levels of B cell infiltration might also benefit
the anti-PD-1/PD-L1-based immunotherapy.
Naïve-like B cells inhibit cell proliferation of NSCLC
To assess the direct effects of the naïve-like B cells on tumor cells, we applied the flow
cytometry sorting using antibodies against the CD20 to obtain the naïve-like B cells in
NSCLC tissues. The naïve-like B cells in 8 fresh NSCLC tumor tissues, including 4
stage I and 4 stage III tumor tissues, were sorted. We then co-cultured the naïve-like B
cells with lung cancer cell lines A549 and H1299 in vitro. Cell viability of the A549 and
H1299 cells after the co-culture with CD20+ B cells was examined at 24 h. The co-
culture with CD20+ B cells significantly inhibited the growth of A549 and H1299 cells
(P < 0.001) (Fig. 4a, Additional file 1: Figure S3a).
Fig. 4 Naïve-like B cells inhibit the cell growth in lung cancer. a Naïve-like B cells inhibit cell growth of
A549 cells. The left panel showed the experimental design. The cell growth of A549 cells co-cultured with
or without CD20+ B cells was determined by CCK8 assays (right panel). b Naïve-like B cells inhibit cell
growth of A549 cells in a cell-cell interaction-independent manner. The left panel showed the experimental
design. The cell growth of A549 cells treated with or without culture supernatants of CD20+ B cells was
determined by CCK8 assays (right panel). c t-SNE plots showing the expression and distribution of
SERPINA9, VNN2, IFI30, and PIK3AP1 in single-cell RNA-seq analysis of lung tumor. d Determination of VNN2
and SERPINA in the culture media of naïve-like B cells from patients’ tissues. B cells isolated from PBMC
were used as control (ctrl). e Overexpression of VNN2, IFI30, PIK3AP1, and SERPINA9 inhibited the cell
growth of A549 cells
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Since the effects of immune cells on malignant cells could be achieved either by a dir-
ect cell-cell interaction or via soluble mediators such as factors and cytokines, we ex-
tracted the culture supernatant of the CD20+ B cells isolated from the NSCLC tissue
and then used it to treat the A549 and H1299 cells for 24 h. We found the culture
supernatant of the CD20+ B cells also suppressed the growth of A549 and H1299 cells
(Fig. 4b, Additional file 1: Figure S3b), indicating the effects of the CD20+ B cells on
lung cancer cells can be independent of cell-cell interaction and also suggesting that
the CD20+ B cell-secreted proteins might contribute to the tumor-suppressive function
of CD20+ B cells in NSCLC.
To further determine which factors secreted by B cells were involved in the regula-
tion of tumor cells, we firstly analyzed the genes abundantly expressed in the CD20+ B
cells. 1426 highly expressed genes in CD20+ B cells were identified, and 66 uniquely
expressed genes were identified (Fig. 4c). We then acquired the human secreted protein
in the Uniprot database and overlapped the highly expressed genes in the CD20+ B cells
with the annotated secreted proteins. Four secreted proteins were uniquely expressed
in the CD20+ B cells, including VNN2 (Vanin 2), IFI30 (Gamma-Interferon-Inducible
Protein IP-30), PIK3AP1 (B Cell Adaptor Protein), and SERPINA9 (Serpin Family A
Member 9) (Fig. 4c). Next, to confirm the secretion of SERPINA9 and VNN2 from
CD20+ B cells, we determined the protein level of SERPINA9 and VNN2 in the culture
media of B cells. We found that SERPINA9 and VNN2 were enriched (Fig. 4d), indicat-
ing the secretion of these proteins by CD20+ B cells in NSCLC.
Next, we tried to determine the effects of these four proteins on tumor cells. How-
ever, due to the limited commercialized protein of these four proteins, we were unable
to check the direct effects of these four proteins on tumor cells. We thus overexpressed
these genes in A549 and H1299 lung cancer cell lines to test the effects of these pro-
teins on NSCLC cells. We found that the overexpression of SERPINA9 and VNN2
inhibited the growth of A549 and H1299 cells (Fig. 4e, Additional file 1: Figure S3c).
Plasma-like B cells in the advanced-stage NSCLC promote tumor cell proliferation while
those in the early-stage NSCLC partially inhibit the proliferation
To further identify the effects of the plasma-like B cells on the tumor progression of
NSCLC, we sorted the plasma-like B cells from three stage I tumor tissues and three
stage III tumor tissues using antibodies against BCMA, a marker identified to be
uniquely expressed in the plasma-like B cells in our scRNA-seq data. We then co-
cultured the plasma-like B cells with A549 and H1299 cell lines. Interestingly, we found
that the plasma-like B cells from stage III promote proliferation while the plasma-like B
cells from stage I inhibit proliferation of A549 and H1299 cells (Fig. 5a, Additional file 1:
Figure S4a), implying pro-tumor effects of plasma-like B cells in stage III NSCLC and a
tumor-suppressive effects of the plasma-like B cells in stage I NSCLC .
To test whether the effects exerted by these plasma-like B cells relied on a direct cell-
cell interaction or through the secreted molecules, we collected the culture superna-
tants of plasma-like B cells isolated from stage I or stage III NSCLC and then treated
the A549 and H1299 cells. We also found that the culture supernatants of plasma-like
B cells isolated from stage I inhibited the cell growth of A549 and H1299 cells, while
the culture supernatants of plasma-like B cells isolated from stage III promoted the cell
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growth of A549 and H1299 cells (Fig. 5b, Additional file 1: Figure S4b), indicating that
the effects exerted by the plasma-like B cell also can be attributed to the secreted
molecules.
As the scRNA-seq demonstrated a high level expression of IGHG1, IGHG4 gene (en-
coding the IgG proteins) in the plasma-like B cells (Fig. 2d). We next determined the
IgG and IgA expression of the culture media of these plasma-like B cells and observed
a very high level of IgG (Fig. 5c). To ascertain the function of IgG, we isolated the IgG
from different stages of NSCLC (Fig. 5d) and treated the A549 with these IgG. We
found that the IgG isolated from stage I NSCLC exerts minor toxic effects on A549
cells while the IgG isolated from stage III NSCLC significantly accelerated the growth
of A549 cells (Fig. 5e). Together, these observations suggested that the effect of
plasma-like B cells in different stages of NSCLC might function differently on tumor
cells, and the effects were mainly attributed to the secreted IgGs.
Identification of the targets of pathology immunoglobulins
To illustrate the function of these IgGs produced by plasma-like B cells, we further identi-
fied the targets of the IgGs in cancer cells. We performed an immunoprecipitation using
Fig. 5 IgG-producing plasma-like B cells exert a different effect on tumor cells in different stages of lung
cancer. a IgG-producing plasma-like B cells isolated from patient at stage III lung cancers promote
proliferation of A549 cells. The left panel shows a schematic of the experiment design. CD20−BCMA+ B cells
isolated from stage I or stage III lung tumors were co-cultured with A549 cells, and the cell growth was
determined by CCK8 assays (right panel). b The function of CD20−BCMA+ B cells on A549 cells was exerted
in a cell-cell interaction-independent manner. The left panel showed a schematic of the experiment design.
The culture supernatant of the CD20−BCMA + B cells isolated from stage I or stage III lung tumors was used
to treat A549 cells, and the cell growth was determined by CCK8 assays (right panel). c The level of IgG
produced by plasma-like B cells had no significant difference between stage I and stage III. The amount of
IgG was determined by ELISA experiments. d The pathology IgG in stage I and stage III exerts different
functions on A549 cells. The left panel showed a schematic of the experiment design. The purified IgG was
validated by western blot using antibodies against the human IgG (right panel). e The pathology IgG
isolated from stage III NSCLC but not stage I promoted the cell growth of A549 cells
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the endogenous IgG produced by the plasma-like B cells in 8 NSCLC tissues, including 4
stage I and 4 stage III NSCLC. We firstly performed cell lysis on tumor samples, which
contains the IgGs and the target proteins of these IgGs as well, and precipitated these
IgGs as well as their targets using magnetic protein A/G beads. The precipitated proteins
were then subjected to for proteomics analysis (Fig. 6a). A total of 637 proteins were iden-
tified (Additional file 4: Table S3).
These proteins could be classified into three groups: the IgG protein, the IgG-binding
proteins, and the targets of the IgGs (Fig. 6b). The LC-MS/MS was further validated by
western blot (Fig. 6c). The IgG proteins are directly captured by the protein A/G beads,
including the IGHG and IGHL. The IgG-binding proteins are proteins which directly
interacted with IgG, mainly the Fc-binding proteins. These proteins bind to the IgG
through the Fc-domain of IgG and trigger the downstream biological events. We next
Fig. 6 Identification of the pathologic targets. a Schematic illustration of the identification of the targets of
pathologic antibodies. b Representative illustration of the proteins that interacted with pathologic
antibodies. c Validation of the proteins bound by the pathologic antibodies. d The macrophages in the
microenvironment of the NSCLC mainly belong to the M2 macrophages. The expression of M2
macrophage-specific marker CD163 and MRC1 (CD206) in the single-cell dataset was plotted. e
Overexpression of AP2A1 results in increased endocytosis of IgGs. Left panel shows the experimental
design. A549 cells were transduced with AP2A1 overexpression or vector plasmid and treated with IgG.
Cellular IgGs were determined by western blot (right panel). f A549 cell lines were electroporated with PBS
(ctrl), pathology RHOC IgGs, and RHOC-IgG depleted IgGs, and the whole cell lysates were harvested 3 h
after electroporation. The expression levels of RHOC and TRIM21 were determined by western blot. GAPDH
was used as the internal control. g A549 cell lines were electroporated with PBS (ctrl) or recombinant rabbit
antibodies against RHOC, and the whole cell lysates were harvested 3 h after electroporation. The
expression levels of RHOC and TRIM21 were determined by western blot. GAPDH was used as the internal
control. h Schematic of TRIM21-mediated degradation of specific targets in tumor cells
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analyzed the expression of these Fc-binding proteins across different cell types and
found that the Fc-binding proteins were mainly expressed by monocytes or macro-
phages (Additional file 1: Figure S5), such as C1QA, C1QB, C1QC, FCGR3A, and
FCGR1C, which might contribute to the antibody-dependent cellular cytotoxicity.
We checked the characteristic of the macrophages infiltrated in the microenviron-
ment of NSCLC. The macrophages in NSCLC tissues express high levels of M2 macro-
phage markers, including CD163 and CD206 (MRC1) (Fig. 6d), which functions by
promoting the tumorigenesis other than anti-tumorigenesis. Since the antibody-
dependent cell-mediated cytotoxicity (ADCC) mainly attributed by the M1 macro-
phages, these antibodies were most likely not be able to initiate the ADCC in the
microenvironment of NSCLC, despite a potential interaction with the macrophages.
We next explored the ADCC-independent function of these antibodies. Many new
targets of IgGs in lung cancer were non-cell surface proteins, but we noticed that many
targets of these IgGs were adaptor proteins, such as the AP-2 complex including
AP2A1, AP2A2, AP2B1, AP2S1, and AP2M1(Fig. 6b). As the AP-2 complex was mainly
reported to be involved in endocytosis, it is tempting to speculate that some IgGs might
be endocytosed to other cells via the AP-2 complexes. To test this hypothesis, we first
determined the expression of AP-2 in the microenvironment of lung cancers. The AP-2
protein is highly expressed in the tumor cells as well as the monocytes in lung cancer
(Additional file 1: Figure S5). Next, to assess the role of AP-2 in the transportation of
IgGs, we applied a cellular model for IgG determination. We overexpressed the AP2A1,
a core component of AP2 complex that was highly expressed in tumor tissue of lung
cancers, in A549 cells and added purified human IgGs to cell culturing media. The
IgGs were significantly increased in cells with AP2A1 overexpression (Fig. 6e), indicat-
ing the IgGs would be delivered into tumor cells in an AP2-dependent manner.
Next, to address the potential functions of the IgGs transported into tumor cells, we
reviewed the IgG-binding proteins identified in the aforementioned protein-omics and
cellular function of IgGs. We noticed that TRIM21, an Fc-binding protein involved in
ubiquitin-dependent antibodies-targets degradation [29], was significantly enriched in
the targets of pathology IgGs (Fig. 6b, Additional file 4: Table S3). Thus, it is tempting
to speculate that the pathology IgGs might contribute to the degradation of specific tar-
gets via its association of TRIM21 in tumor cells. To address this possibility, we choose
Rhoc as one of the representative cellular targets of IgGs identified in LC-MS/MS to-
gether with the expression of these targets in tumor cells using the scRNA-seq results
(Fig. 6b, Additional file 1: Figure S5, Additional file 4: Table S3). Rhoc was reported to
be an oncogene that was overexpressed in NSCLC cells and involved in tumor cell pro-
liferation and metastasis.
We electroporated the pathology Rhoc IgGs and the Rhoc-depleted IgGs into A549
and H1299 cells, respectively. We found that the expression of Rhoc was significantly
decreased upon Rhoc-IgG treatment, but the inhibition was decreased upon deletion of
Rhoc-IgG (Fig. 6f). Furthermore, we electroporated a monoclonal rabbit anti-human
Rhoc IgGs into A549 cells and observed similar results as the pathology Rhoc-IgG
(Fig. 6g), suggesting the pathology Rhoc-IgG might trigger the TRIM21 pathway and
lead to degradation of the Rhoc proteins. Together, these results suggest a novel role of
IgGs on tumor cells, i.e., the IgGs could be delivered into the tumor cells with the help
of AP2 complex. The imported IgGs recognized their targets through the Fab-domains
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while the Fc-domains interact with TRIM21 and triggered the ubiquitin-mediated deg-
radation of RHOC in tumor cells (Fig. 6h).
Discussion
Immune checkpoint inhibitor has achieved significant success in treating melanoma
and blood cancers, but its efficacy on solid cancer types remains relatively low [3, 30].
B cell is one major class of immune cells in the adaptive immune systems and has mul-
tiple functions in facilitating the co-evolution of cancer and its microenvironment.
However, the functions of tumor-infiltrating B cells remain incompletely characterized.
Here, we identified novel subtypes of B cells infiltrated in NSCLC via a single-cell
RNA-seq experiment, and revealed multiple novel functions of subtypes of tumor-
infiltrated B cells in NSCLC, including (I) the infiltrated B cells could be divided into
two classes with distinct gene expression signatures, (II) CD20+ B cells inhibit tumor
growth in NSCLC, (III) the IgGhigh B cells produce immunoglobulin and inhibit cell
growth in the early stage of NSCLC but may promote cell growth in the advanced stage
of NSCLC, (IV) proteomics profiling identified the novel targets and functions of the
pathological antibodies produced by plasma-like B cells, and (V) the pathological anti-
body could be imported into tumor cells via AP2 complexes and degrade its targets
through the TRIM21-mediated ubiquitin pathway.
Although CD20 and CD19 are the most prevalently used markers of B cells, we iden-
tified a subset of CD20−CD19−CD79A+CD79B+ B cells in NSCLC. Comparing to
CD19/CD20-positive B cells, CD79A/CD79B are more generally expressed in the B
cells through different maturation and function stages [31]. We identified that the
CD20+ B cells were mainly located in TLS. TLS density is positively correlated with pa-
tient’s favorable clinical outcome in lung cancer. Recent studies also suggested that
TLS formation is associated with cancer patients’ response to immunotherapy [32–35].
Our results revealed that the CD20+ B cells may inhibit the growth and progression of
tumor cells in the early disease stage, and positively correlated with good prognosis of
NSCLC. We also identified overly expressed secreted proteins, such as VNN2, IFI30,
PIK3AP1, and SERPINA9, in the CD20+ B cells. Current studies in tumor-associated B
cells, such as the regulatory B cells, mainly focused on the secretion of IL-10 and TGF-
β, which might contribute to the function of T cells and therapy effect of T cell-
mediated immune response [36]. Our study revealed that the CD20+ B cells in the
microenvironment of lung cancers produce a high level of VNN2 and SERPINA9 and
directly inhibit the growth of NSCLC cells. A possible future direction is to comprehen-
sively characterize the functions of the proteins secreted by CD20+ B cells.
Clinically, our studies emphasized on the prognostic impact of naïve-like B cells as
well as the roles of the genes uniquely expressed by naïve-like B cells, such as TLR10,
FCRL1, BLK, and TNFRSF13B in NSCLC. Previous studies have revealed infiltrated B
cells are related with poor prognosis of gastric cancer [37] and prostate cancer [38], but
with favorable prognosis of NSCLC and breast cancer [39]. Here, by integrating our
single-cell transcriptomic data with TCGA data, we further confirmed that the
CD20+CD79A+ B cells were a favorable factor in NSCLC. Our newly identified CD20+
B cells and their uniquely expressed genes could potentially be used to predict patients’
prognosis of NSCLC.
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We demonstrated the versatile functions of B cell in NSCLC via a series of experi-
ments, suggesting targeting a distinct subset rather than complete B cell might be a fu-
ture perspective for B cell-based immune therapy. Moreover, our single-cell
transcriptomics data also provides a reference map of genes that uniquely expressed in
the distinct subtype of B cells in NSCLC comparing to the B cells collected from blood
samples. Another future direction is to interpret the distinct function of the plasma-
like specific, as well as the specifically expressed genes (such as CD38, MZB1), and their
possible roles in cell-cell interactions and cancer-microenvironment co-evolution in
NSCLC.
We also presented a novel mechanism for endocytosis of antibodies in the tumor
cells of NSCLC. Our analysis revealed that the antibodies directly bound to the AP-2
complexes in lung tumors. The AP2 (assembly polypeptide 2) complex is one of the
most abundant adaptors and a major player in clathrin-mediated endocytosis [40]. Pre-
vious studies have revealed its role in the regulation of endocytosis of integrins [41]. In
this study, we found that immunoglobulin directly interacted with AP2 complex in
NSCLC, and overexpressed AP2 increased the cellular immunoglobulin levels, suggest-
ing the direct involvement of AP2 in the endocytosis of immunoglobulins in the tumor
cells of NSCLC. While the function of immunoglobulin in targeting extracellular pro-
teins has been intensively studied, the role of cellular immunoglobulin in tumor cells
remains largely unknown. We demonstrated that the immunoglobulins directly inter-
acted with TRIM21 (Tripartite Motif Containing 21). TRIM21 is an E3 ubiquitin-
protein ligase and a cytosolic Fc receptor, which bound to the Fc-chains of antibody
and deliver ubiquitin-proteasome to Fab-recognizing targets [29]. A recent study finds
that antibody-TRIM21-ubiquitin-proteasome could be used as a tool for the degrad-
ation of specific targets [42]. We reported that the pathology Rhoc antibody could be
delivered into the tumor cells and resulted in decreased Rhoc protein levels in NSCLC
cell lines. Since the Rhoc mainly functions as an oncogene, the imported Rhoc anti-
bodies might negatively regulate tumor progression, suggesting a potential anti-tumor
role of these IgGs.
In summary, our studies identified multiple novel insights of B cell subtypes and im-
munoglobulins in regulating the progression of NSCLC. The newly established versatile
function of B cells, as well as the antibodies, highlighted possible clinical implications
of targeting B cell subtypes in the microenvironment of NSCLC. In addition, our
single-cell transcriptome and proteomics profiling immunoglobulin-antigen provide
important resources for future investigation of B cells and other immune/stromal cells
in NSCLC, which may eventually benefit the clinical practice.
Methods
Human tumor specimens
A total of 164 paraffin-embedded samples of primary NSCLC were collected from
NSCLC patients from 2012 to 2013 at the Shanghai Pulmonary Hospital. None of these
patients received any anti-cancer therapy before tumor resection. The patients’ relapse-
free survival (RFS) and overall survival (OS) durations were defined as the period from
initial surgery to clinically proven metastasis or recurrence and death, respectively. The
median patient follow-up time was 63months after surgery (range, 5–81months).
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Cell lines
A549 and NCI-H1299 cells were obtained from the cell bank of Chinese Academy of
Science. These cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco).
All cell lines used in this study were authenticated by STR sequencing. Cells were rou-
tinely tested, and all were mycoplasma negative.
Single-cell transcriptome profiling
The single-cell suspension of tumors was obtained by digesting with 2 mg/mL collage-
nase in DMEM supplemented with 10% FBS. Non-digestible tissues were filtered with
the 70-μm Cell Strainer (BD Falcon). The mononuclear cell was then separated using
the Ficoll-Paque PLUS density gradient media (GE health). Single-cell library was con-
structed with the Chromium Single Cell 3′ Reagent Kits (v2 Chemistry) according to
manufacturer’s instructions. Libraries were sequenced at the illumine platforms. The
data matrix of each single cells was analyzed using the Cell Ranger Pipelines.
Briefly, raw sequences were processed with Cell Ranger (version 3.0.2), a package that
takes Illumina bcl or fastq files as input and generates a count matrix after filtered er-
rors and biases. Filtered reads were aligned to the human genome (GRCh38) with
STAR [43], a high-performance community-standard aligner. After alignment, reads
were translated into a UMI matrix. The matrix of read counts per gene per sample was
further analyzed by the Seurat suite (version 3.1.0) [44] in the R program (version
3.6.0). A total of 144,271 cells that passed quality control steps implemented in Cell
Ranger were obtained. We further applied a quality control to get highly reliable cells;
cells meeting any of the following criteria were excluded: < 500 or > 6000 unique genes
expressed, > 40,000 UMIs, or > 50% of reads mapping to the mitochondria. These steps
removed an additional 28,726 cells, resulting in a final dataset of 115,545 cells. We
quantified gene expression across 35,538 genes, of which 19,540 were expressed in at
least one cell.
To keep a standard procedure for clustering, we used a value of 0.5 for the resolution.
To investigate transcriptional heterogeneity and to undertake initial cell clustering, we
applied a dimensionality reduction with principal component analysis (PCA). We se-
lected the top 30 principal components (PCs) that explained more variability than ex-
pected by chance using a permutation-based test in Seurat. For the cell clustering
within primary clusters (subclustering), we selected variable numbers of PCs for dimen-
sionality reduction using either permutation-based analyses or heuristic methods in
Seurat. We used PC loadings as input for a graph-based approach to cluster cells by cell
type and as input for uniform manifold approximation and projection (UMAP) for re-
duction to two dimensions for visualization purposes.
Cluster-specific genes were acquired using the FindMarkers algorithm in the Seurat
suite. Test used for cell marker identification was ROC analysis. Cell types of each clus-
ter were determined by scMatch [27] and manually checked with known cell surface
markers. The PBMC scRNA-seq datasets were obtained from the database of 10X gen-
omics (https://support.10xgenomics.com/single-cell-gene-expression/datasets). The
clusters expressing CD79A or MS4A1 were identified as B cells. Cell barcodes of the B
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cell clusters and corresponding gene counts were extracted for generating B cell ex-
pression matrix.
Identification of the correlation of gene expression with the survival of LUAD in TCGA
cohorts
The expression of each gene and the clinical information of each patient with LUAD
were obtained from the TCGA cohorts [45]. The coefficient values were obtained from
OncoLnc database (http://www.oncolnc.org/download/). The top 10 genes in each clus-
ter of the scRNA-seq data were used for plotting of the Cox coefficient values. The
average of the Cox values of the 10 genes in each cluster was calculated.
Flow cytometry
The single-cell suspension of tumors was isolated as described above. Non-digestible
tissues, as well as the pellets of dead cells, were filtered with the 70-μm Cell Strainer
(BD Falcon). Surface staining was performed with anti-CD79A (562,852, BD #300412)
and anti-CD20 (561741, BD Biosciences #560273) antibodies. Cells were then resus-
pended in 400 μL PBS and analyzed on LSRII flow cytometer (BD Biosciences).
Histology, immunohistochemistry (IHC), immunofluorescence (IF)
Serial 4-mm-thick formalin-fixed paraffin-embedded (FFPE) tissue sections were baked
in a drying oven at 60 °C for 1 h. Then, they were deparaffinized in xylene and rehy-
drated in decreasing concentrations of ethanol. Tissue sections were incubated in re-
trieval solution (citrate buffer, pH 6) for antigen retrieval at 95 C for 30 min. Tissue
sections were incubated in 3% hydrogen peroxide and in serum-free protein block solu-
tion (Dako, X0909) before adding the primary antibody (CD20, ab78237, abcam;
CD79A, ab199001, abcam) for 1 h at room temperature. After signal amplification
using biotinylated-secondary antibody and streptavidin-horseradish peroxidase, slides
were counterstained with hematoxylin, mounted with a glycerol-based mounting
medium, and scanned for digital imaging. The TILs were composed of mononuclear
cells, including lymphocytes. Intra-alveolar macrophages were not considered as part of
the immune infiltration [32]. All IHC results were independently scored by two pathol-
ogists (Prof. Likun Hou and Chunyan Wu). In case of disagreement, the slides were re-
examined until the observers reached a consensus. A semiquantitative manual scoring
was used to evaluate the percentage of TILs exhibiting membrane staining (positive
staining proportion score). The overall infiltration of the naïve-like B cells was quanti-
fied by multiplication of the ratio of CD20+CD79+ double-positive cells among the TILs
cells. We defined the ratio > 10% as naïve-like Bhigh cells, while the ratio ≤ 10% as
naïve-like Blow cells. Meanwhile, immunofluorescence was performed using anti-
CD79A (562852, BD) and anti-CD20 (555622, BD) antibodies. Immunofluorescent im-
ages were recorded with a LeicaTCS-SP5 confocal laser scanning microscope (Heidel-
berg, Germany). All immunostained slides and matching hematoxylin and eosin-stained
sections were scanned with the MoticEasyScan digital scanner.
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Western blot analysis
Total protein was isolated using RIPA solution (Beyotime Biotechnology, Jiangsu,
China), and BCA protein assay kit (Beyotime Biotechnology, Jiangsu, China) was ap-
plied to detect the concentration of the protein. Equal amounts of the protein (50 μg)
were spotted into 10% SDS-PAGE gel for electrophoresis, followed transferred onto
PVDF membranes. Then, the membranes were soaked into 5% milk for an hour at
room temperature. Subsequently, membranes were incubated at 4 °C overnight with
primary antibodies against primary antibody, After that, the membranes were washed
by PBS and incubated with HRP-tagged secondary antibody for 1 h. The proteins were
then detected using ECL reagent (Pierce Biotechnology, USA). GAPDH levels served as
loading controls. All experiments were repeated in triplicate. Primary antibodies were
as follows: anti-human AP2A1 (ab61, Abcam), anti-human RHOC (#3430, Cell Signal
Technology), and anti-human TRIM21 (ab207728, Abcam).
B cell isolation and stimulation
The mononuclear cells among tumors were separated using the Ficoll-Paque PLUS
density gradient media (GE health). The pellets of dead cells were filtered with the 40-
μm Cell Strainer (BD Falcon). And the mononuclear cells were stained with anti-
BCMA (357503, Biolegend) or anti-CD20 (555622, BD Biosciences) antibodies. BCMA-
positive or CD20-positive cells were sorted with the BD FACSAria II. The sorted cells
were cultured in RPMI 1640 Medium supplemented with 10% FBS and 200 U/mL
penicillin-streptomycin. After being sorted for 24 h, cells were centrifuged and resus-
pended in fresh RPMI 1640 Medium supplemented with 10% FBS. The supernatant of
sorted cells was collected 48 h after culture. For co-culture experiments, the sorted cells
were co-cultured with A549 and H1299 cells in DMEM supplemented with 10% FBS
for 48 h. After 48 h of co-culture, B cell-containing culture media were removed and re-
placed with fresh culture media and cultured for further 4 h, and the cell viability of
A549 and H1299 cells was determined by CCK8 assays.
Purification of immunoglobulin by affinity chromatography
The tumors were lysed in dounce homogenizer with IP buffer (20 mM Tris-HCL (PH
8.0), 2 mM EDTA, 1% Triton-X100, 150 mM NaCl, 1× proteinase inhibitor cocktail).
The supernatants were collected and subjected to IgG-target isolation. Maganic Protein
G beads were added to the tumor lysate and incubated at 4 °C overnight. For western
blotting and LC-MS/MS, the beads were washed with IP buffer for 5 times and boiled
in 2× SDS loading buffer. Purification of the pathology anti-RHOC was performed as
described. Briefly, the GST-RHOC was immobilized with GSTrap HP columns. After
loading with IgG isolated from tumors, the column was washed twice with binding buf-
fer. The non-bound immunoglobulin and elutions were collected.
Statistical analysis
GraphPad Prism 7.0a was used for statistical analysis with the RT-qPCR results, IHC
quantification, flow cytometry analysis, OD45 data, and survival analysis. P values from
unpaired two-tailed Student’s t tests were used for estimating the statistical significance
between different groups. P values from the log-rank test were used for survival analysis.
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